USPTO serial 79411782
HAEMA PLASMA
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Aug 26, 2025
- Examiner
- CORWIN, KEVIN SCOTT
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with HAEMA PLASMA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Deborah L. Shapiro
Deborah L. Shapiro Moses & Singer LLP405 Lexington AvenueThe Chrysler BuildingNew York, NY 10174Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Medicines, in particular medicines made from blood components, fractions and preparations, with said medicines being for the treatment of diseases and disorders of the blood; Blood components, fractions and preparations, namely, blood for medical purposes, blood plasma, and blood substitutes for human use; Blood components, fractions and preparations for injection, namely, blood for medical purposes, blood plasma, and blood substitutes for human use; Blood components, fractions and preparations for automatic transplantation, namely, blood for medical purposes, blood plasma, and blood substitutes for human use; Blood components, fractions and preparations for transfusion, namely, blood for medical purposes, blood plasma, and blood substitutes for human use; Blood components, fractions and preparations for immunotherapy, namely, blood for medical purposes, blood plasma, and blood substitutes for human use; Blood components, fractions and preparations for autologous transfusion, namely, blood for medical purposes, blood plasma, and blood substitutes for human use; Blood, blood fractions and blood components for medical, therapeutic, and prophylactic purposes, namely, blood for medical purposes, blood plasma, and blood substitutes for human use; Blood plasma; Cells for medical use, namely, blood cell preparations; Health care substances and preparations, in particular for haematology, namely, pharmaceuticals for the treatment of blood diseases and disorders, blood for medical purposes, blood plasma, and blood substitutes for human use; Finished medical products, namely, blood for human use and blood plasma; Preparations for medical purposes, in particular haematology preparations namely, pharmaceuticals for the treatment of blood diseases and disorders, blood for medical purposes, blood plasma, and blood substitutes for human use; Immunotherapeutic and immunoprophylactic preparations, namely, pharmaceuticals for treating immunological diseases and disorders; Living cells for medical purposes, namely, leukocyte preparations of white blood cells; Living cells and cell fragments for medical purposes, namely, platelet and red blood cell concentrates; Blood plasma, namely, quarantine plasma and fractionated plasma; Clinical medical reagents for processing human blood and blood components for use in blood transfusions and for extracorporeal blood processing stored in bags, bottles, syringes and similar containers for storing substances such as these for medical purposes; Pharmaceutical products and haematology preparations including those for the treatment of blood and blood components, in particular infusion and transfusion solutions in the nature of blood, blood plasma, and blood substitutes for human use and pharmaceuticals for the treatment of blood diseases and disorders; Pharmaceutical blood plasma preparations for the treatment of blood diseases, blood disorders; Pharmaceutical blood preparations for the treatment of blood diseases, blood disorders; Pharmaceutical blood products, namely, pharmaceuticals for the treatment of blood diseases, blood disorders; Cell material for autotransplantation and autotransfusion, cells for medical use; Cell material for transplantation and transfusion, namely, cells for medical use; Cell material for medical, therapeutic and prophylactic purposes, namely, cells for medical purposes | ACTIVE | — |
| 035 | Updating and maintenance of blood donor data in computer databases | ACTIVE | — |
| 042 | Technical provision and support for data processing systems, namely, providing technology information in the field of data processing and technical support services in the nature of troubleshooting computer software problems in connection with data processing; Providing temporary use of online, non-downloadable software for accessing patient treatment databases and donor databases; Providing technological and scientific information about scientific laboratory services and blood banks, in particular medical research laboratories; Providing of scientific information derived from analysis of medical diagnostic results; Blood analysis services for scientific research purposes; Scientific laboratory services; Chemical laboratories and medical research laboratories; Scientific research in the field of physics; Chemistry services, namely, chemical analysis, chemical laboratories; Chemical analysis; Scientific testing services, namely, blood testing for scientific research purpose; Blood testing for scientific research purposes, with said testing entailing the filtration, separation and centrifugation of blood; Laboratory trials, namely, medical and scientific research in the nature of conducting clinical trials for others; Development and further development of data processing computer software and hardware in the field of laboratory medicine and blood and plasma collection; Database development services, namely, creation of medical databases in digital form; Scientific and medical research in the medical and pharmaceutical fields; Scientific and medical research in the field of chemistry and biology; Development and establishment of testing specifications and procedures for the medical industry, namely, development of medical equipment procedures and test procedures, donation procedures, and medical instrument procedures; Data processing services, namely, technical and scientific registration and processing of patient treatment data and donor data in databases; Scientific laboratory services | ACTIVE | — |
| 044 | Medical analysis services for diagnostic and treatment purposes provided by medical laboratories in connection with blood and plasma donation and clinical medical consultations in connection with the same; Clinical medical consultation services in relation to transfusion medicine; pharmacy advice; Providing of medical information in relation to blood donation centres; Providing of medical and pharmaceutical support via telephone, namely, providing medical information generally; Medical services featuring blood fractionation or treatment; Medical services in the nature of blood sampling and collection; blood testing services being medical analysis services for diagnostic and treatment purposes provided by medical laboratories; Pharmacy services, namely, preparation of prescriptions in pharmacies; Medical assistance; Blood bank services; Blood bank services in the nature of blood donation centres; Blood bank services in the nature of blood extraction stations; Services in the field of immunotherapy, namely, medical care; Consulting services in the field of medical care, namely, consultancy in relation to transfusion medicine and clinic hygiene, medical transfusion consultancy in clinics, in particular consultancy by doctors administering transfusions, medical transfusion testing; Medical care, namely, immunotherapy; Providing medical information, namely, medical diagnostic information through medical results; Medical care, namely, conducting medical diagnostics within the framework of conducting medical examinations; Blood bank services, namely, collecting of blood donations, including platelet donations, SDR donation being erythrocyte donation, whole blood donation, plasma donation, and autologous donation being multiple types of cellular donations from an individual; Medical care, namely, execution of medical and clinical examination services; Dietetic advisory services; Providing medical opinions in the nature of medical advice in the field of weight loss, dermatology, hematology; Health counselling; Medical care, namely, transfusion or transplantation of blood and blood components; Medical services; Medical care, namely, the use of medical equipment, instruments and apparatus for medical care purposes; Blood bank services, namely, services of packed red blood cell banks; Blood bank services, namely, services of platelet concentrate banks; Blood bank services, namely, services of leukocyte banks; Blood bank services, namely, services of blood plasma banks and collection and preservation of blood for medical and diagnostic purposes; Blood bank services, namely, blood component banks; Medical services, namely, extraction of stem cells | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Haema GmbH
- Other trademarks owned by Haema GmbH
- Other trademarks owned by Haema GmbH
- Other trademarks owned by Haema AG
- Other trademarks in Class 005
- Other trademarks in Class 035
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named HAEMA PLASMA
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 28, 2026 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| May 11, 2026 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| May 11, 2026 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Apr 2, 2026 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Mar 15, 2026 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Mar 15, 2026 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Nov 26, 2025 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Aug 26, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Aug 26, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jul 8, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 8, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 2, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jun 3, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 2, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 2, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 2, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 18, 2025 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Feb 15, 2025 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jan 27, 2025 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jan 27, 2025 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Dec 27, 2024 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Dec 26, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 21, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 12, 2024 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Dec 12, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 12, 2024 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |